PEPG · PepGen Ltd
-
-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US7133171055 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 467M |
|---|---|
| PE Ratio | None |
| Target Price | 10 |
| Beta | 1.91 |
| Dividend Yield | None |
ABOUT
PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Learn More